Articles by Walter Armstrong, Senior Editor - Pharmaceutical Executive


Articles by Walter Armstrong, Senior Editor

Walter Armstrong, Senior Editor

Glaxo Vies for a Second Act in HIV
November 4, 2009

A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.

Gilead Buys CV Therapeutics (Update 1)
March 12, 2009

The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion.

Pfizer's Full-Court Press to Save Chantix
June 4, 2008

Badly wounded by mounting fears of its safety profile and plunging prescriptions, Pfizer?s novel smoking-cessation drug that promised blockbuster sales is now fighting for its life?with a no-holds-barred ad and PR campaign.

ASCO's Take-Home and the Oncology Market
June 4, 2008

With cancer pharma?s most competitive category, the big news from the annual oncology confab can big changes in the market outlook. Two Decision Resources analyst round it up and break it down.

Social Networking Site for Cancer Docs: Bang or bust?
June 4, 2008

MedTrust Online is pitching customized Web sites linking primary-care physicians to one another, oncology specialists, and a trove of medical content has grabbed a lot of press. Can it fly?

Pharma Forecast: Into the Woods
January 1, 2008

Pharm Exec asks experts to predict what 2008 has up its sleeve for the industry--from the top line to the bottom line, from R&D to M&As, from Congress to the courts.

The List
December 1, 2007

It's that time of year again, when Santas everywhere take stock of nice and naughty in order to fill stockings—and magazines make up their lists of hits and has-beens.

Is Merck's Long Vioxx Nightmare Really Over?
November 14, 2007

A prominent pharma litigator argues that Merck's settlement was predictable from the start. And it has a chance of success—provided that it survives a key legal challenge and can meet its mark with plaintiff sign-on.

Lilly's New Blood Thinner No Blockbuster
November 6, 2007

Safety Risks, Generic Threat Scale Down Big Hopes


Click here